ANT-INTERNATIONAL
1.7.2024 15:13:29 CEST | Business Wire | Press release
MultiSafepay (MSP), an Amsterdam-based payment service provider, and Antom global merchant payment services (Antom), a leading payment and digitization services provider under Ant International, announced today that MultiSafepay has become a wholly-owned subsidiary of Ant International and will integrate with Antom to promote convenient, secure and accessible payment solutions and digitalization services to businesses, especially small and medium-sized enterprises (SMEs) across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701540843/en/
Olaf Geurs, CEO of MultiSafepay (left) and Gary Liu, General Manager of Antom Global (right), in a ceremony. (Photo: Business Wire)
MultiSafepay now serves merchants with omnichannel payment services connecting over 40 international payment methods, including cards, e-wallets, Buy-Now, Pay-Laters, internet banking, and more. Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. In addition to flexible, secure and reliable payment options, Antom brings a suite of marketing and digitalization services to empower local and regional businesses with more growth opportunities.
Through this strategic partnership, MultiSafepay will leverage Antom’s cutting edge technology and digital capabilities to further expand its product offerings and SME merchant coverage in the region.
Since 1999, MultiSafepay has been a pioneer simplifying payment for SME businesses. It provides world-class payment solutions to over 18,000 SMEs, empowering them to concentrate on their business while MSP optimizes payment success rates, payment handling and processing combined with a personal approach.
Olaf Geurs, CEO of MultiSafepay said, “The past 25 years have been an incredible journey. Together with our amazing team, we've bootstrapped MultiSafepay into a leading full-service PSP in Europe, overcoming countless obstacles along the way. The entrepreneurial spirit never sleeps, which is why we're partnering with Antom to unlock even greater growth potential for MultiSafepay's products and services, attracting even more businesses to our ecosystem.”
Gary Liu, General Manager of Antom Global said, “We are thrilled to join hands with MultiSafepay, a trusted industry innovator and our long-term partner. SMEs are the pillar of regional and global prosperity. With digital innovations, we look forward to building together more secure, flexible and efficient payment solutions with cross-sector partners, for small businesses to thrive in a truly inclusive and sustainable global commerce ecosystem.”
About MultiSafepay
MultiSafepay is a leading Netherlands-based payment services provider using cutting-edge in-house-developed technology to help businesses of all sizes focus on growth and innovation. It offers European companies a simple, tailored payments ecosystem for online, in-person, and omnichannel solutions through a single platform and integration. MultiSafepay offers a personal approach to payments, optimizing payment success rates and reducing complexities to allow businesses and platforms to concentrate and drive their growth.
About Antom
Ant International’s Antom is a leading provider of payment and digitization services to merchants worldwide. Antom provides one-stop, vertical-specific digital payment solutions to meet the payment needs for merchants of all sizes, especially SMEs. With a presence in over 150 markets, Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. Antom also provides digital marketing solutions and merchant digitization services to help merchant in digital operations and to better engage with their customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701540843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom